Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director · President and CEO | August 10, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 391,489 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Sale · Disposed 89,090 · Balance 391,489 F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 13, 2026 01:27 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 89,090 | $17.10 | $1,523,439.00 |
DisclosureSEC source: 0001493152-26-037484 · ownership.xml · nonDerivative · entry 1 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,489 F1 · kind: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 7,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000246 · wk-form4_1783375318.xml · derivative · entry 5 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,743 Underlying: Ordinary Shares · 7,743 shares Expires 2029-06-01 F3 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 7,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000246 · wk-form4_1783375318.xml · derivative · entry 4 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,741 Underlying: Ordinary Shares · 7,741 shares Expires 2028-06-01 F3 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 7,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000246 · wk-form4_1783375318.xml · derivative · entry 3 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,741 Underlying: Ordinary Shares · 7,741 shares Expires 2027-06-01 F3 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantOrdinary Shares | 22,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000246 · wk-form4_1783375318.xml · nonDerivative · entry 2 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,800 F2 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in three equal annual installments beginning on June 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:02 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 50,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000246 · wk-form4_1783375318.xml · nonDerivative · entry 1 Kim Julie So-Young · CIK 0001977732 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,579 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 10:04 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 105,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000128 · wk-form4_1777370695.xml · nonDerivative · entry 1 Kim Julie So-Young · CIK 0001977732 · CEO - Elect 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,145 F1 · kind: On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. F2 · balance_after: Includes 256,372 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (175,526 shares), July 1, 2027 (52,218 shares) and July 1, 2028 (28,628 shares). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.